TransCode Therapeutics, Inc. (RNAZ) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering TransCode Therapeutics, Inc. (RNAZ), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For TransCode Therapeutics, Inc., analysts forecast revenue rising from $300,000 in 2024 to $27.80M in 2029; the average estimate for 2029 earnings per share is −$5.04; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
TransCode Therapeutics, Inc. (RNAZ) forecast — frequently asked questions
What are analysts forecasting for TransCode Therapeutics, Inc.'s earnings?
The average analyst estimate for TransCode Therapeutics, Inc. (RNAZ) earnings per share in 2029 is -5.04, with individual estimates between -5.04 and -5.04.
How much revenue is TransCode Therapeutics, Inc. expected to make?
Analysts forecast TransCode Therapeutics, Inc. (RNAZ) revenue of $27.80M in 2029, based on 1 published estimates.
How many analysts cover RNAZ?
1 analyst contribute estimates for TransCode Therapeutics, Inc. (RNAZ). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.